BIAFW · bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. operates at the intersection of precision diagnostics and artificial intelligence, commercializing CyPath® Lung — a noninvasive, sputum-based flow cytometry assay designed to detect early-stage lung cancer with clinically meaningful sensitivity (92%) and specificity (87%) in patients with small pulmonary nodules. Its business model centers on laboratory service revenue generated through its wholly owned, CAP-accredited and CLIA-certified subsidiary Precision Pathology Laboratory Services (PPLS), which performs the test commercially. The company’s market opportunity is anchored in the urgent need for improved early detection: lung cancer remains the leading cause of cancer-related deaths globally, and current screening protocols often lead to unnecessary biopsies or delayed intervention. bioAffinity’s competitive moat rests on proprietary automation pipelines, clinical validation data, and integration into established pathology workflows — though it faces competition from imaging modalities, liquid biopsies, and emerging molecular assays. Financially, the filing discloses no revenue, net income, or margin figures directly; however, the March 13, 2026 audit report by WithumSmith+Brown, PC explicitly raises substantial doubt about the company’s ability to continue as a going concern — a material red flag indicating acute liquidity pressure and dependence on future financing. This context frames the offering’s purpose: it is not a capital-raising event for the company, but a resale registration enabling selling stockholders to monetize securities issued in prior private placements — specifically 365,603 Warrant Shares and 131,880 Conversion Shares resulting from anti-dilution adjustments. While bioAffinity stands to receive up to ~$1.6 million in gross proceeds if all registered warrants are exercised for cash, it receives zero proceeds from secondary sales — underscoring that this S-1 serves liquidity needs of investors, not operational funding. Governance reflects typical biotech structures: dual-class features are absent, but protective provisions include Delaware’s Section 203 anti-takeover statute, charter-level exculpation for directors, and exclusive Delaware Chancery forum selection. Leadership includes seasoned executives with deep diagnostic and pathology backgrounds, though the company’s reliance on third-party clinical sites (e.g., Brooke Army Medical Center, Walter Reed) and recent relocation of UTSA-based research due to lease non-renewal signal operational fragility. Collectively, the filing reveals a technically differentiated but financially precarious company navigating the high-stakes transition from clinical validation to scalable commercialization — where execution risk, reimbursement uncertainty, and capital discipline will determine whether its AI-augmented diagnostics achieve durable market traction.